AI Summary & Key Takeaways
AI InsightIn addition, regardless of the vaccine type, being vaccinated with any of them decreased the incidence of SARS-CoV-2 infection and the mortality rate.
📌 3 Key Takeaways
Abstract
This study has investigated the vaccination rates against SARS-CoV-2 infection, antibody response to vaccine types, and factors affecting mortality in maintenance hemodialysis patients.98 of 143 patients undergoing hemodialysis in our clinic had 3 doses of BNT162b2 (Pfizer-BioNTechh) or CoronaVac (Sinovac Life Sciences) vaccine. Of these 98 patients, blood samples were obtained from 52 patients who agreed to obtain serum samples before and after vaccination. The serum samples were analyzed using the Abbott SARS-CoV-2 immunoassay designed to detect IgG antibodies against the receptor-binding domain of the S1 subunit of the spike protein of SARS-CoV-2. The rate of vaccination with at least one dose of vaccine was 85.3%, and the frequency of SARS-CoV-2 infection was 58.7%. The patients whose antibody titer was obtained after the third dose of vaccine (n=52) were divided into two groups according to the last vaccine type, as BioNTechh group of 16 patients and the Sinovac group of 36 patients. Considering all 52 patients with 3 doses of vaccine, the median antibody level was 397.3 (min-max) (4.5-40000) before the third vaccine dose, while 1325.3 (min-max) (10.5-40000) after the third vaccine dose (P<0.001). In patients with the last vaccine dose of Sinovac (n=36), the median antibody titer was 168.2 (min-max) (4.5-40000) before the third vaccine dose, while 851.7 (min-max) (55.2-40.000) after the third vaccine dose (P<0.01). In patients with the last vaccine dose of BioNTechh, the median antibody titer was 2738.6 (min-max) (9.4-37723.4) before the third vaccine dose, while 37575.8 (min-max) (10.5-40000) after the third vaccine dose (P=0.002). The frequency of SARS-CoV-2 infection (P=0.001) and SARS-CoV-2 infection-related mortality rates were significantly lower in vaccinated patients than in unvaccinated patients (P<0.001). SARS-CoV-2 vaccine doses elicited a high seropositive response in patients receiving maintenance dialysis. Those who received the last (3rd) dose of vaccine with BNT162b2 had higher antibody levels than those with CoronaVac/Sinovac. In addition, regardless of the vaccine type, being vaccinated with any of them decreased the incidence of SARS-CoV-2 infection and the mortality rate.
Özet
This study has investigated the vaccination rates against SARS-CoV-2 infection, antibody response to vaccine types, and factors affecting mortality in maintenance hemodialysis patients.98 of 143 patients undergoing hemodialysis in our clinic had 3 doses of BNT162b2 (Pfizer-BioNTechh) or CoronaVac (Sinovac Life Sciences) vaccine. Of these 98 patients, blood samples were obtained from 52 patients who agreed to obtain serum samples before and after vaccination. The serum samples were analyzed using the Abbott SARS-CoV-2 immunoassay designed to detect IgG antibodies against the receptor-binding domain of the S1 subunit of the spike protein of SARS-CoV-2. The rate of vaccination with at least one dose of vaccine was 85.3%, and the frequency of SARS-CoV-2 infection was 58.7%. The patients whose antibody titer was obtained after the third dose of vaccine (n=52) were divided into two groups according to the last vaccine type, as BioNTechh group of 16 patients and the Sinovac group of 36 patients. Considering all 52 patients with 3 doses of vaccine, the median antibody level was 397.3 (min-max) (4.5-40000) before the third vaccine dose, while 1325.3 (min-max) (10.5-40000) after the third vaccine dose (P<0.001). In patients with the last vaccine dose of Sinovac (n=36), the median antibody titer was 168.2 (min-max) (4.5-40000) before the third vaccine dose, while 851.7 (min-max) (55.2-40.000) after the third vaccine dose (P<0.01). In patients with the last vaccine dose of BioNTechh, the median antibody titer was 2738.6 (min-max) (9.4-37723.4) before the third vaccine dose, while 37575.8 (min-max) (10.5-40000) after the third vaccine dose (P=0.002). The frequency of SARS-CoV-2 infection (P=0.001) and SARS-CoV-2 infection-related mortality rates were significantly lower in vaccinated patients than in unvaccinated patients (P<0.001). SARS-CoV-2 vaccine doses elicited a high seropositive response in patients receiving maintenance dialysis. Those who received the last (3rd) dose of vaccine with BNT162b2 had higher antibody levels than those with CoronaVac/Sinovac. In addition, regardless of the vaccine type, being vaccinated with any of them decreased the incidence of SARS-CoV-2 infection and the mortality rate.